UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (date of earliest event reported):
February
16, 2009
CHEMED
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
1-8351 |
31-0791746 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
2600 Chemed Center, 255 East 5th Street, Cincinnati, OH 45202 |
(Address of principal executive offices) (Zip Code) |
Registrant’s
telephone number, including area code:
(513) 762-6900
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2 below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Page 1 of 2
Item
2.02 Results of Operations and Financial Condition
On February 16, 2009 Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2008. A copy of the release is furnished herewith as Exhibit 99.
Item
9.01 Financial Statements and Exhibits
d) Exhibit
(99) Registrant's press release dated February 16, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CHEMED CORPORATION |
||
|
|||
Dated: |
February 16, 2009 |
By: |
/s/ Arthur V. Tucker, Jr. |
Arthur V. Tucker, Jr. |
|||
Vice President and Controller |
Page 2 of 2
Exhibit 99
Chemed Reports Fourth-Quarter 2008 Results
CINCINNATI--(BUSINESS WIRE)--February 16, 2009--Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest provider of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2008, versus the comparable prior-year period, as follows:
Consolidated operating results from continuing operations:
VITAS segment operating results:
Roto-Rooter segment operating results:
VITAS
Congress has recently approved The American Recovery and Reinvestment Act of 2009. The President has stated that he intends to sign this stimulus package on Tuesday, February 17, 2009. This Act provides for an increase in the Medicare hospice wage index for the period October 1, 2008, through September 30, 2009. Given the timing of the passage of this Act, VITAS has not included any adjustment to fourth-quarter 2008 revenue for this increase in Medicare hospice reimbursement.
Net revenue for VITAS was $206 million in the fourth quarter of 2008, which is an increase of 4.4% over the prior-year period. This revenue growth was the result of increased ADC of 1.4% and a Medicare price increase of approximately 2.6%. The remaining difference is attributed to revenue mix.
Average revenue per patient per day in the quarter was $189.37, which is 3.0% above the prior-year period. Routine home care reimbursement and high acuity care averaged $149.26 and $665.38, respectively, per patient per day in the fourth quarter of 2008. During the quarter, high acuity days-of-care were 7.8% of total days-of-care. Quarterly high acuity days-of-care averaged between 8.0% and 8.4% in 2007.
VITAS did not have any Medicare Cap liability for the 2008 measurement period ended September 28, 2008. VITAS has recorded $235,000 of Medicare Cap liability related to the first three months of the 2009 cap measurement period. This Medicare Cap liability relates to one provider number that has a gross margin in excess of 20%. Admissions in this provider number have declined in the first three months of the 2009 Medicare Cap year. This program generated a 15% cap cushion over the prior 12-month period.
Of VITAS’ 34 unique Medicare provider numbers, 29 provider numbers, or 85%, have a Medicare Cap cushion greater than 20% for the most recent 12-month period, four provider numbers have 15% to 20% cushion and one provider number has cap cushion of less than 10%. VITAS generated an aggregate cap cushion of $220 million during calendar year 2008.
Gross margin in the fourth quarter of 2008 was 25.1%. This is 192 basis points above the fourth quarter of 2007. This margin increase is a result of improved management of scheduled labor. VITAS continues to focus on more efficient scheduling of direct labor. This involves utilization of field-based labor management tools designed to meet and respond to hospice team staffing requirements.
Selling, general and administrative expense was $17.2 million in the fourth quarter of 2008, which is a decline of 0.3% when compared to the prior year. Adjusted EBITDA totaled $34.3 million, an increase of 20.7% over the prior year and equates to an adjusted EBITDA margin of 16.7%.
Roto-Rooter
Roto-Rooter’s plumbing and drain cleaning business generated sales of $86 million for the fourth quarter of 2008, 2.5% lower than the $89 million reported in the comparable prior-year quarter. Adjusted EBITDA in the fourth quarter of 2008 totaled $15.5 million, a decrease of 19.0% from the fourth quarter of 2007, and equated to an adjusted EBITDA margin of 17.9%.
Job count in the fourth quarter of 2008 declined 12.5% when compared to the prior-year period. Total residential jobs declined 12.2% and consisted of residential plumbing jobs decreasing 11.0% and residential drain cleaning jobs declining 12.8%, when compared to the fourth quarter of 2007. Residential jobs represent approximately 70% of total job count. Total commercial jobs declined 13.3% with commercial plumbing job count declining 13.2% and commercial drain cleaning decreasing 13.7%, when compared to the prior-year quarter.
This job count decline was significantly mitigated relative to total revenue through a combination of increased pricing, favorable job mix shift to more expensive jobs such as excavation and increased conversion rates of calls to paid jobs.
There continues to be substantial disparity in demand for Roto-Rooter services within the United States. The South region has experienced a 17.3% year-to-date decline in commercial jobs while the Northeast Region had a modest 2.7% decline in commercial volume. Residential demand is not as disparate, with the South region residential job count declining 13.5% while the remaining regions have experienced a job count decline ranging from 6% to 11%.
Management continues to have discussions with existing franchisees to acquire Roto-Rooter franchise territories. This increase in activity is attributed to the current state of the capital markets, the potential increase in tax rates and the recessionary difficulties our franchisees are experiencing. The timing or actual completion of these acquisitions cannot be predicted; however, management intends to be highly disciplined in terms of valuation and risk assessment to ensure these acquisitions will be accretive to shareholders.
Chemed Consolidated Debt and Cash Flows
Chemed’s debt aggregated $210 million at December 31, 2008, $187 million of which carries a fixed interest rate of 1.875% and is due in May 2014. The remaining debt consists of a $14.5 million bank term loan and $8.2 million of debt drawn against Chemed’s $175 million revolving credit facility. The current interest rate on this debt is approximately 1.4%.
Chemed’s $175 million revolving credit facility expires in May 2012. At December 31, 2008, this credit facility had approximately $140 million of undrawn borrowing capacity after deducting for $8.2 million of borrowing and $27 million of letters of credit issued under this facility to secure the Company’s workers’ compensation insurance.
Chemed’s total debt divided by the trailing four quarters of Adjusted EBITDA reflects a debt leverage ratio of 1.3.
Effective January 1, 2009, the Company will be required to retrospectively adopt the provisions of FASB Staff Position No. APB 14-1, “Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion (Including Partial Cash Settlement).” This new rule requires the Company to separately account for the debt and equity portions of its 1.875% Senior Convertible Notes (Notes). This accounting creates a discount on the Notes that will be recorded in equity at the inception of the debt. The Notes, net of this discount, will be accreted to their face value over the life of the Notes using the effective interest method. The impact of this accounting change for the year ended December 31, 2009, is projected to be a non-cash increase in pretax interest expense of approximately $ 6.0 million ($3.8 million after-tax).
Year-to-date net cash provided from operations aggregated $112 million. Capital expenditures for 2008 aggregated $26 million and compares favorably to total 2007 capital expenditures of $27 million. Chemed’s full-year 2008 depreciation and amortization aggregated $28 million.
Guidance for 2009
Congress has recently approved The American Recovery and Reinvestment Act of 2009. This Act provides for an increase in the Medicare hospice wage index for the period October 1, 2008, through September 30, 2009. This 2009 guidance includes approximately $8 million in additional revenue related to this adjustment in the Medicare hospice reimbursement rate.
VITAS is estimated to generate full-year 2009 revenue growth, prior to Medicare Cap, of 6.0% to 7.5%. Admissions are estimated to increase 2% to 4% and full-year adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 15.3% to 16.3%. This guidance assumes VITAS will receive a Medicare basket price increase of 1.5% effective October 1, 2009. Full calendar year 2009 Medicare contractual billing limitations are estimated at $5.0 million.
Roto-Rooter is estimated to generate full-year 2008 revenue growth of 4.0% to 5.0%. The revenue growth is a result of increased pricing of 4.0% to 5.0% and a favorable mix shift to higher revenue jobs, partially offset by a job count decline estimated at 7.0% to 9.0% Adjusted EBITDA margin for 2009 is estimated in the range of 17.0% to 18.0%. This guidance does not include any Roto-Rooter franchise acquisitions that may be completed in 2009.
Chemed’s effective tax rate has been impacted by the severe volatility in the stock market as it relates to certain deferred compensation investments and required GAAP tax accounting. This stock market volatility does not have any material impact on Chemed’s reported pretax earnings. Excluding the impact of taxes associated with this deferred compensation issue, Chemed’s effective tax rate for full-year 2009, is estimated at 39.0%.
Based upon these factors and a full-year average diluted share count of 22.8 million shares, management estimates 2009 earnings per diluted share from continuing operations, excluding noncash expenses for stock options, the non-cash increase in interest expense related to the accounting change for convertible debt interest expense and the tax rate impact from deferred compensation investments will be in the range of $3.70 to $3.95.
Conference Call
Chemed will host a conference call and webcast at 10 a.m., ET, on Tuesday, February 17, 2009, to discuss the company's quarterly results and provide an update on its business. The dial-in number for the conference call is (800) 884-5695 for U.S. and Canadian participants and (617) 786-2960 for international participants. The participant passcode is 91895366. A live webcast of the call can be accessed on Chemed's website at www.chemed.com by clicking on Investor Relations Home.
A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. It can be accessed by dialing (888) 286-8010 for U.S. and Canadian callers and (617) 801-6888 for international callers and will be available for one week following the live call. The replay passcode is 53390517. An archived webcast will also be available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to approximately 12,000 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.
Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing and drain service through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in Indonesia, Singapore, Japan, and the Philippines.
This press release contains information about Chemed’s EBITDA and adjusted EBITDA, which are not measures derived in accordance with generally accepted accounting principles and which exclude components that are important to understanding Chemed’s financial performance. Chemed provides EBITDA and adjusted EBITDA to help investors and others evaluate its operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s EBITDA and adjusted EBITDA should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. A reconciliation of Chemed’s net income to its adjusted EBITDA is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements. These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed’s dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||
CONSOLIDATED STATEMENT OF INCOME | ||||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||||||
For the Three Months Ended | For the Years Ended | |||||||||||||||||||||||
December 31, | December 31, | |||||||||||||||||||||||
2008 | 2007 | 2008 | 2007 | |||||||||||||||||||||
Continuing Operations | ||||||||||||||||||||||||
Service revenues and sales | $ | 292,205 | $ | 285,729 | $ | 1,148,941 | $ | 1,100,058 | ||||||||||||||||
Cost of services provided and goods sold (aa) | 201,150 | 197,221 | 810,547 | 767,066 | ||||||||||||||||||||
Selling, general and administrative expenses (aa) | 42,263 | 47,374 | 175,333 | 184,060 | ||||||||||||||||||||
Depreciation | 5,332 | 5,221 | 21,581 | 20,118 | ||||||||||||||||||||
Amortization | 1,491 | 1,369 | 5,924 | 5,270 | ||||||||||||||||||||
Other operating expenses--net (aa) | 2,699 | 1,927 | 2,699 | 789 | ||||||||||||||||||||
Total costs and expenses | 252,935 | 253,112 | 1,016,084 | 977,303 | ||||||||||||||||||||
Income from operations | 39,270 | 32,617 | 132,857 | 122,755 | ||||||||||||||||||||
Interest expense | (1,396 | ) | (1,587 | ) | (5,985 | ) | (11,244 | ) | ||||||||||||||||
Gain/(loss) on extinguishment of debt (aa) | 4,208 | - | 4,208 | (13,798 | ) | |||||||||||||||||||
Other income--net | (6,524 | ) | 1,057 | (8,735 | ) | 4,125 | ||||||||||||||||||
Income before income taxes | 35,558 | 32,087 | 122,345 | 101,838 | ||||||||||||||||||||
Income taxes (aa) | (15,471 | ) | (11,882 | ) | (50,240 | ) | (39,063 | ) | ||||||||||||||||
Income from continuing operations | 20,087 | 20,205 | 72,105 | 62,775 | ||||||||||||||||||||
Discontinued Operations (bb) |
(1,088 | ) | - | (1,088 | ) | 1,201 | ||||||||||||||||||
Net Income | $ | 18,999 | $ | 20,205 | $ | 71,017 | $ | 63,976 | ||||||||||||||||
Earnings Per Share | ||||||||||||||||||||||||
Income from continuing operations | $ | 0.90 | $ | 0.84 | $ | 3.13 | $ | 2.56 | ||||||||||||||||
Net Income | $ | 0.85 | $ | 0.84 | $ | 3.08 | $ | 2.61 | ||||||||||||||||
Average number of shares outstanding | 22,382 | 23,959 | 23,058 | 24,520 | ||||||||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||||||
Income from continuing operations | $ | 0.89 | $ | 0.83 | $ | 3.08 | $ | 2.50 | ||||||||||||||||
Net Income | $ | 0.84 | $ | 0.83 | $ | 3.04 | $ | 2.55 | ||||||||||||||||
Average number of shares outstanding | 22,644 | 24,460 | 23,374 | 25,077 | ||||||||||||||||||||
(aa) |
Included in the consolidated statement of income are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
|||||||||||||||||||||||
|
||||||||||||||||||||||||
For the Three Months Ended | For the Years Ended | |||||||||||||||||||||||
December 31, | December 31, | |||||||||||||||||||||||
2008 | 2007 | 2008 | 2007 | |||||||||||||||||||||
Continuing Operations | ||||||||||||||||||||||||
Costs of services provided and goods sold | ||||||||||||||||||||||||
Unreserved prior year's insurance claim | $ | - | $ | - | $ | (597 | ) | $ | - | |||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||||||
Stock option expense | (2,219 | ) | (1,591 | ) | (7,303 | ) | (4,665 | ) | ||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
(2 | ) | (39 | ) | (46 | ) | (227 | ) | ||||||||||||||||
Long-term incentive compensation | - | - | - | (7,067 | ) | |||||||||||||||||||
Other | - | - | - | 467 | ||||||||||||||||||||
Other operating expenses -- net | - | |||||||||||||||||||||||
Impairment loss on transportation equipment | (2,699 | ) | - | (2,699 | ) | - | ||||||||||||||||||
Costs related to litigation settlement | - | (1,927 | ) | - | (1,927 | ) | ||||||||||||||||||
Gain on sale of property | - | - | - | 1,138 | ||||||||||||||||||||
Gain/(loss) on extinguishment of debt | 4,208 | - | 4,208 | (13,798 | ) | |||||||||||||||||||
Pretax impact on earnings | (712 | ) | (3,557 | ) | (6,437 | ) | (26,079 | ) | ||||||||||||||||
Income tax benefit on the above | 270 | 1,355 | 2,382 | 9,623 | ||||||||||||||||||||
Income tax impact of nondeductible losses on investments held in deferred compensation trusts |
(1,825 | ) | 77 | (3,062 | ) | (46 | ) | |||||||||||||||||
Income tax credit related to prior years | - | - | 322 | - | ||||||||||||||||||||
After-tax impact on continuing operations | $ | (2,267 | ) | $ | (2,125 | ) | $ | (6,795 | ) | $ | (16,502 | ) | ||||||||||||
(bb) |
Discontinued operations for 2008 include adjustments to accruals related to operations discontinued in 2004 and prior years. For 2007 it represents accrual adjustments for VITAS Phoenix, discontinued in 2006. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||
CONSOLIDATED BALANCE SHEET | ||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||
December 31, | ||||||||||||||||||
2008 | 2007 (cc) | |||||||||||||||||
Assets | ||||||||||||||||||
Current assets | ||||||||||||||||||
Cash and cash equivalents | $ | 3,628 | $ | 4,988 | ||||||||||||||
Accounts receivable less allowances | 98,076 | 101,170 | ||||||||||||||||
Inventories | 7,569 | 6,596 | ||||||||||||||||
Current deferred income taxes | 15,392 | 14,212 | ||||||||||||||||
Prepaid expenses and other current assets | 11,596 | 10,496 | ||||||||||||||||
Total current assets | 136,261 | 137,462 | ||||||||||||||||
Investments of deferred compensation plans held in trust | 22,628 | 29,417 | ||||||||||||||||
Notes receivable | - | 9,701 | ||||||||||||||||
Properties and equipment, at cost less accumulated depreciation | 76,962 | 74,513 | ||||||||||||||||
Identifiable intangible assets less accumulated amortization | 61,303 | 65,177 | ||||||||||||||||
Goodwill | 448,721 | 438,689 | ||||||||||||||||
Other assets | 15,049 | 15,411 | ||||||||||||||||
Total Assets | $ | 760,924 | $ | 770,370 | ||||||||||||||
Liabilities | ||||||||||||||||||
Current liabilities | ||||||||||||||||||
Accounts payable | $ | 52,810 | $ | 46,168 | ||||||||||||||
Current portion of long-term debt | 10,169 | 10,162 | ||||||||||||||||
Income taxes | 2,156 | 4,221 | ||||||||||||||||
Accrued insurance | 35,994 | 36,337 | ||||||||||||||||
Accrued compensation | 40,741 | 40,072 | ||||||||||||||||
Other current liabilities | 12,180 | 13,929 | ||||||||||||||||
Total current liabilities | 154,050 | 150,889 | ||||||||||||||||
Deferred income taxes | 7,597 | 5,802 | ||||||||||||||||
Long-term debt | 199,656 | 214,669 | ||||||||||||||||
Deferred compensation liabilities | 22,417 | 29,149 | ||||||||||||||||
Other liabilities | 5,612 | 5,512 | ||||||||||||||||
Total Liabilities | 389,332 | 406,021 | ||||||||||||||||
Stockholders' Equity | ||||||||||||||||||
Capital stock | 29,515 | 29,261 | ||||||||||||||||
Paid-in capital | 282,206 | 267,312 | ||||||||||||||||
Retained earnings | 343,810 | 278,336 | ||||||||||||||||
Treasury stock, at cost | (285,977 | ) | (213,041 | ) | ||||||||||||||
Deferred compensation payable in Company stock | 2,038 | 2,481 | ||||||||||||||||
Total Stockholders' Equity | 371,592 | 364,349 | ||||||||||||||||
Total Liabilities and Stockholders' Equity | $ | 760,924 | $ | 770,370 | ||||||||||||||
Book Value Per Share | $ | 16.58 | $ | 15.21 | ||||||||||||||
(cc) Reclassified to conform to 2008 presentation. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS | |||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||
For the Years Ended | |||||||||||||||||
December 31, | |||||||||||||||||
2008 | 2007 (cc) | ||||||||||||||||
Cash Flows from Operating Activities | |||||||||||||||||
Net income | $ | 71,017 | $ | 63,976 | |||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||||||||||||
Depreciation and amortization | 27,505 | 25,388 | |||||||||||||||
Provision for uncollectible accounts receivable | 9,820 | 8,373 | |||||||||||||||
Stock option expense | 7,303 | 4,665 | |||||||||||||||
Noncash loss/(gain) on early extinguishment of debt |
(4,208 |
) |
7,235 |
||||||||||||||
Loss on impairment of equipment | 2,699 | - | |||||||||||||||
Discontinued operations | 1,088 | (1,201 | ) | ||||||||||||||
Amortization of debt issuance costs | 1,039 | 1,186 | |||||||||||||||
Provision for deferred income taxes | 426 | 8,113 | |||||||||||||||
Noncash portion of long-term incentive compensation | - | 6,154 | |||||||||||||||
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: |
|||||||||||||||||
Increase in accounts receivable | (6,659 | ) | (18,299 | ) | |||||||||||||
Increase in inventories | (898 | ) | (18 | ) | |||||||||||||
Decrease/(increase) in prepaid expenses and other current assets |
305 | (549 | ) | ||||||||||||||
Increase/(decrease) in accounts payable and other current liabilities |
5,585 | (8,416 | ) | ||||||||||||||
Increase/(decrease) in income taxes | (770 | ) | 6,321 | ||||||||||||||
Decrease/(increase) in other assets | 5,481 | (3,655 | ) | ||||||||||||||
Increase/(decrease) in other liabilities | (6,423 | ) | 4,426 | ||||||||||||||
Excess tax benefit on share-based compensation | (2,422 | ) | (3,091 | ) | |||||||||||||
Other sources/(uses) | 1,195 | (1,024 | ) | ||||||||||||||
Net cash provided by operating activities | 112,083 | 99,584 | |||||||||||||||
Cash Flows from Investing Activities | |||||||||||||||||
Capital expenditures | (26,094 | ) | (26,640 | ) | |||||||||||||
Business combinations, net of cash acquired | (11,200 | ) | (1,079 | ) | |||||||||||||
Net proceeds/(uses) from disposals of discontinued operations | 8,824 | (5,402 | ) | ||||||||||||||
Proceeds from sales of property and equipment | 387 | 3,104 | |||||||||||||||
Other uses | (544 | ) | (1,701 | ) | |||||||||||||
Net cash used by investing activities | (28,627 | ) | (31,718 | ) | |||||||||||||
Cash Flows from Financing Activities | |||||||||||||||||
Purchases of treasury stock | (69,788 | ) | (131,704 | ) | |||||||||||||
Repayment of long-term debt | (18,713 | ) | (225,709 | ) | |||||||||||||
Net increase in revolving line of credit |
8,200 | - | |||||||||||||||
Dividends paid | (5,543 | ) | (5,888 | ) | |||||||||||||
Excess tax benefit on share-based compensation | 2,422 | 3,091 | |||||||||||||||
Decrease in cash overdraft payable | (856 | ) | (919 | ) | |||||||||||||
Proceeds from exercise of stock options | 291 | 2,467 | |||||||||||||||
Proceeds from issuance of long-term debt | - | 300,000 | |||||||||||||||
Purchase of note hedges | - | (55,100 | ) | ||||||||||||||
Proceeds from issuance of warrants | - | 27,614 | |||||||||||||||
Debt issuance costs | - | (6,949 | ) | ||||||||||||||
Other sources | (829 | ) | 945 | ||||||||||||||
Net cash used by financing activities | (84,816 | ) | (92,152 | ) | |||||||||||||
Decrease in Cash and Cash Equivalents | (1,360 | ) | (24,286 | ) | |||||||||||||
Cash and cash equivalents at beginning of year | 4,988 | 29,274 | |||||||||||||||
Cash and cash equivalents at end of year | $ | 3,628 | $ | 4,988 | |||||||||||||
(cc) Reclassified to conform to 2008 presentation. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||
FOR THE THREE MONTHS ENDED DECEMBER 31, 2008 AND 2007 | ||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||
Chemed | ||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||
2008 | ||||||||||||||||||||
Service revenues and sales | $ | 205,856 | $ | 86,349 | $ | - | $ | 292,205 | ||||||||||||
Cost of services provided and goods sold | 154,159 | 46,991 | - | 201,150 | ||||||||||||||||
Selling, general and administrative expenses (a) | 17,230 | 25,261 | (228 | ) | 42,263 | |||||||||||||||
Depreciation | 3,231 | 2,045 | 56 | 5,332 | ||||||||||||||||
Amortization | 996 | 14 | 481 | 1,491 | ||||||||||||||||
Other operating expense/(income) (a) | - | - | 2,699 | 2,699 | ||||||||||||||||
Total costs and expenses | 175,616 | 74,311 | 3,008 | 252,935 | ||||||||||||||||
Income/(loss) from operations | 30,240 | 12,038 | (3,008 | ) | 39,270 | |||||||||||||||
Interest expense | (37 | ) | (30 | ) | (1,329 | ) | (1,396 | ) | ||||||||||||
Intercompany interest income/(expense) | 1,337 | 876 | (2,213 | ) | - | |||||||||||||||
Gain on extinguishment of debt (a) | - | - | 4,208 | 4,208 | ||||||||||||||||
Other income—net | (101 | ) | 3 | (6,426 | ) | (6,524 | ) | |||||||||||||
Income/(loss) before income taxes | 31,439 | 12,887 | (8,768 | ) | 35,558 | |||||||||||||||
Income taxes (a) | (11,900 | ) | (4,740 | ) | 1,169 | (15,471 | ) | |||||||||||||
Income/(loss) from continuing operations | 19,539 | 8,147 | (7,599 | ) | 20,087 | |||||||||||||||
Discontinued operations, net of income taxes | - | - | (1,088 | ) | (1,088 | ) | ||||||||||||||
Net income/(loss) | $ | 19,539 | $ | 8,147 | $ | (8,687 | ) | $ | 18,999 | |||||||||||
2007 (f) | ||||||||||||||||||||
Service revenues and sales | $ | 197,202 | $ | 88,527 | $ | - | $ | 285,729 | ||||||||||||
Cost of services provided and goods sold | 151,476 | 45,745 | - | 197,221 | ||||||||||||||||
Selling, general and administrative expenses (b) | 17,288 | 25,229 | 4,857 | 47,374 | ||||||||||||||||
Depreciation | 3,069 | 2,075 | 77 | 5,221 | ||||||||||||||||
Amortization | 996 | 13 | 360 | 1,369 | ||||||||||||||||
Other operating expense/(income) (b) | - | 1,927 | - | 1,927 | ||||||||||||||||
Total costs and expenses | 172,829 | 74,989 | 5,294 | 253,112 | ||||||||||||||||
Income/(loss) from operations | 24,373 | 13,538 | (5,294 | ) | 32,617 | |||||||||||||||
Interest expense | (43 | ) | 1 | (1,545 | ) | (1,587 | ) | |||||||||||||
Intercompany interest income/(expense) | 1,902 | 1,317 | (3,219 | ) | - | |||||||||||||||
Other income—net | 23 | 43 | 991 | 1,057 | ||||||||||||||||
Income/(loss) before income taxes | 26,255 | 14,899 | (9,067 | ) | 32,087 | |||||||||||||||
Income taxes (b) | (9,484 | ) | (5,161 | ) | 2,763 | (11,882 | ) | |||||||||||||
Net income/(loss) | $ | 16,771 | $ | 9,738 | $ | (6,304 | ) | $ | 20,205 | |||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007 | ||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||
Chemed | ||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||
2008 | ||||||||||||||||||||
Service revenues and sales | $ | 808,445 | $ | 340,496 | $ | - | $ | 1,148,941 | ||||||||||||
Cost of services provided and goods sold | 625,177 | 185,370 | - | 810,547 | ||||||||||||||||
Selling, general and administrative expenses (a) | 67,750 | 95,971 | 11,612 | 175,333 | ||||||||||||||||
Depreciation | 13,000 | 8,294 | 287 | 21,581 | ||||||||||||||||
Amortization | 3,984 | 50 | 1,890 | 5,924 | ||||||||||||||||
Other operating expense/(income) (a) | - | - | 2,699 | 2,699 | ||||||||||||||||
Total costs and expenses | 709,911 | 289,685 | 16,488 | 1,016,084 | ||||||||||||||||
Income/(loss) from operations | 98,534 | 50,811 | (16,488 | ) | 132,857 | |||||||||||||||
Interest expense | (155 | ) | (246 | ) | (5,584 | ) | (5,985 | ) | ||||||||||||
Intercompany interest income/(expense) | 5,199 | 3,708 | (8,907 | ) | - | |||||||||||||||
Gain on extinguishment of debt (a) | - | - | 4,208 | 4,208 | ||||||||||||||||
Other income—net | (149 | ) | 61 | (8,647 | ) | (8,735 | ) | |||||||||||||
Income/(loss) before income taxes | 103,429 | 54,334 | (35,418 | ) | 122,345 | |||||||||||||||
Income taxes (a) | (38,710 | ) | (20,742 | ) | 9,212 | (50,240 | ) | |||||||||||||
Income/(loss) from continuing operations | 64,719 | 33,592 | (26,206 | ) | 72,105 | |||||||||||||||
Discontinued operations, net of income taxes | - | - | (1,088 | ) | (1,088 | ) | ||||||||||||||
Net income/(loss) | $ | 64,719 | $ | 33,592 | $ | (27,294 | ) | $ | 71,017 | |||||||||||
2007 (f) | ||||||||||||||||||||
Service revenues and sales | $ | 755,426 | $ | 344,632 | $ | - | $ | 1,100,058 | ||||||||||||
Cost of services provided and goods sold | 586,435 | 180,631 | - | 767,066 | ||||||||||||||||
Selling, general and administrative expenses (b) | 65,103 | 95,424 | 23,533 | 184,060 | ||||||||||||||||
Depreciation | 11,446 | 8,365 | 307 | 20,118 | ||||||||||||||||
Amortization | 3,984 | 54 | 1,232 | 5,270 | ||||||||||||||||
Other operating expense/(income) (b) | - | 1,927 | (1,138 | ) | 789 | |||||||||||||||
Total costs and expenses | 666,968 | 286,401 | 23,934 | 977,303 | ||||||||||||||||
Income/(loss) from operations | 88,458 | 58,231 | (23,934 | ) | 122,755 | |||||||||||||||
Interest expense | (146 | ) | (495 | ) | (10,603 | ) | (11,244 | ) | ||||||||||||
Intercompany interest income/(expense) | 7,254 | 4,993 | (12,247 | ) | - | |||||||||||||||
Loss on extinguishment of debt (b) | - | - | (13,798 | ) | (13,798 | ) | ||||||||||||||
Other income—net | (11 | ) | 387 | 3,749 | 4,125 | |||||||||||||||
Income/(loss) before income taxes | 95,555 | 63,116 | (56,833 | ) | 101,838 | |||||||||||||||
Income taxes (b) | (35,722 | ) | (24,145 | ) | 20,804 | (39,063 | ) | |||||||||||||
Income/(loss) from continuing operations | 59,833 | 38,971 | (36,029 | ) | 62,775 | |||||||||||||||
Discontinued operations, net of income taxes | 1,201 | - | - | 1,201 | ||||||||||||||||
Net income/(loss) | $ | 61,034 | $ | 38,971 | $ | (36,029 | ) | $ | 63,976 | |||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | |||||||||||||||||||||||
FOR THE THREE MONTHS ENDED DECEMBER 31, 2008 AND 2007 | |||||||||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||||||||
Chemed | |||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||
2008 | |||||||||||||||||||||||
Net income/(loss) | $ | 19,539 | $ | 8,147 | $ | (8,687 | ) | $ | 18,999 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Discontinued operations, net of income taxes | - | - | 1,088 | 1,088 | |||||||||||||||||||
Interest expense | 37 | 30 | 1,329 | 1,396 | |||||||||||||||||||
Income taxes | 11,900 | 4,740 | (1,169 | ) | 15,471 | ||||||||||||||||||
Depreciation | 3,231 | 2,045 | 56 | 5,332 | |||||||||||||||||||
Amortization | 996 | 14 | 481 | 1,491 | |||||||||||||||||||
EBITDA | 35,703 | 14,976 | (6,902 | ) | 43,777 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Impairment loss on transportation equipment | - | - | 2,699 | 2,699 | |||||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
2 | - | - | 2 | |||||||||||||||||||
Stock option expense | - | - | 2,219 | 2,219 | |||||||||||||||||||
Gain on extinguishment of debt | - | - | (4,208 | ) | (4,208 | ) | |||||||||||||||||
Advertising cost adjustment (c) | - | 1,401 | - | 1,401 | |||||||||||||||||||
Interest income | (28 | ) | (25 | ) | (88 | ) | (141 | ) | |||||||||||||||
Intercompany interest income/(expense) | (1,337 | ) | (876 | ) | 2,213 | - | |||||||||||||||||
Adjusted EBITDA | $ | 34,340 | $ | 15,476 | $ | (4,067 | ) | $ | 45,749 | ||||||||||||||
2007 (f) | |||||||||||||||||||||||
Net income/(loss) | $ | 16,771 | $ | 9,738 | $ | (6,304 | ) | $ | 20,205 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Interest expense | 43 | (1 | ) | 1,545 | 1,587 | ||||||||||||||||||
Income taxes | 9,484 | 5,161 | (2,763 | ) | 11,882 | ||||||||||||||||||
Depreciation | 3,069 | 2,075 | 77 | 5,221 | |||||||||||||||||||
Amortization | 996 | 13 | 360 | 1,369 | |||||||||||||||||||
EBITDA | 30,363 | 16,986 | (7,085 | ) | 40,264 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Costs related to litigation settlement | - | 1,927 | - | 1,927 | |||||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
39 | - | - | 39 | |||||||||||||||||||
Stock option expense | - | - | 1,591 | 1,591 | |||||||||||||||||||
Advertising cost adjustment (c) | - | 1,532 | - | 1,532 | |||||||||||||||||||
Interest income | (61 | ) | (19 | ) | (616 | ) | (696 | ) | |||||||||||||||
Intercompany interest income/(expense) | (1,902 | ) | (1,317 | ) | 3,219 | - | |||||||||||||||||
Adjusted EBITDA | $ | 28,439 | $ | 19,109 | $ | (2,891 | ) | $ | 44,657 | ||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | |||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | |||||||||||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007 | |||||||||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||||||||
Chemed | |||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||
2008 | |||||||||||||||||||||||
Net income/(loss) | $ | 64,719 | $ | 33,592 | $ | (27,294 | ) | $ | 71,017 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Discontinued operations, net of income taxes | - | - | 1,088 | 1,088 | |||||||||||||||||||
Interest expense | 155 | 246 | 5,584 | 5,985 | |||||||||||||||||||
Income taxes | 38,710 | 20,742 | (9,212 | ) | 50,240 | ||||||||||||||||||
Depreciation | 13,000 | 8,294 | 287 | 21,581 | |||||||||||||||||||
Amortization | 3,984 | 50 | 1,890 | 5,924 | |||||||||||||||||||
EBITDA | 120,568 | 62,924 | (27,657 | ) | 155,835 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Unreserved insurance claim | - | 597 | - | 597 | |||||||||||||||||||
Impairment loss on transportation equipment | - | - | 2,699 | 2,699 | |||||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
46 | - | - | 46 | |||||||||||||||||||
Stock option expense | - | - | 7,303 | 7,303 | |||||||||||||||||||
Gain on extinguishment of debt | - | - | (4,208 | ) | (4,208 | ) | |||||||||||||||||
Advertising cost adjustment (c) | - | 225 | - | 225 | |||||||||||||||||||
Interest income | (137 | ) | (116 | ) | (490 | ) | (743 | ) | |||||||||||||||
Intercompany interest income/(expense) | (5,199 | ) | (3,708 | ) | 8,907 | - | |||||||||||||||||
Adjusted EBITDA | $ | 115,278 | $ | 59,922 | $ | (13,446 | ) | $ | 161,754 | ||||||||||||||
2007 (f) | |||||||||||||||||||||||
Net income/(loss) | $ | 61,034 | $ | 38,971 | $ | (36,029 | ) | $ | 63,976 | ||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Discontinued operations, net of income taxes | (1,201 | ) | - | - | (1,201 | ) | |||||||||||||||||
Interest expense | 146 | 495 | 10,603 | 11,244 | |||||||||||||||||||
Income taxes | 35,722 | 24,145 | (20,804 | ) | 39,063 | ||||||||||||||||||
Depreciation | 11,446 | 8,365 | 307 | 20,118 | |||||||||||||||||||
Amortization | 3,984 | 54 | 1,232 | 5,270 | |||||||||||||||||||
EBITDA | 111,131 | 72,030 | (44,691 | ) | 138,470 | ||||||||||||||||||
Add/(deduct): | |||||||||||||||||||||||
Long-term incentive compensation | - | - | 7,067 | 7,067 | |||||||||||||||||||
Costs related to litigation settlement | - | 1,927 | - | 1,927 | |||||||||||||||||||
Gain on sale of property | - | - | (1,138 | ) | (1,138 | ) | |||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
227 | - | - | 227 | |||||||||||||||||||
Stock option expense | - | - | 4,665 | 4,665 | |||||||||||||||||||
Loss on extinguishment of debt | - | - | 13,798 | 13,798 | |||||||||||||||||||
Advertising cost adjustment (c) | - | 601 | - | 601 | |||||||||||||||||||
Interest income | (151 | ) | (377 | ) | (2,776 | ) | (3,304 | ) | |||||||||||||||
Intercompany interest income/(expense) | (7,254 | ) | (4,993 | ) | 12,247 | - | |||||||||||||||||
Other | - | - | (467 | ) | (467 | ) | |||||||||||||||||
Adjusted EBITDA | $ | 103,953 | $ | 69,188 | $ | (11,295 | ) | $ | 161,846 | ||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME | ||||||||||||||||||||||
FOR THE YEARS ENDED DECEMBER 31, 2008 AND 2007 | ||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||||||||
December 31, | December 31, | |||||||||||||||||||||
2008 | 2007 | 2008 | 2007 | |||||||||||||||||||
Net income as reported | $ | 18,999 | $ | 20,205 | $ | 71,017 | $ | 63,976 | ||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Discontinued operations | 1,088 | - | 1,088 | (1,201 | ) | |||||||||||||||||
After-tax cost of long-term incentive compensation | - | - | - | 4,427 | ||||||||||||||||||
After-tax impairment loss on transportation equipment | 1,714 | - | 1,714 | - | ||||||||||||||||||
After-tax costs related to litigation settlement | - | 1,168 | - | 1,168 | ||||||||||||||||||
After-tax expenses incurred in connection with O.I.G. investigation |
1 | 24 | 28 | 141 | ||||||||||||||||||
After-tax stock option expense | 1,391 | 1,010 | 4,619 | 2,962 | ||||||||||||||||||
After-tax gain on sale of property | - | - | - | (724 | ) | |||||||||||||||||
After-tax other | - | - | - | (296 | ) | |||||||||||||||||
After-tax loss/(gain) on extinguishment of debt | (2,664 | ) | - | (2,664 | ) | 8,778 | ||||||||||||||||
Income tax impact of non-deductible market losses on investments of deferred compensation trusts |
1,825 | (77 | ) | 3,062 | 46 | |||||||||||||||||
Income tax credit related to prior years | - | - | (322 | ) | - | |||||||||||||||||
After-tax unreserved insurance cost | - | - | 358 | - | ||||||||||||||||||
Adjusted net income | $ | 22,354 | $ | 22,330 | $ | 78,900 | $ | 79,277 | ||||||||||||||
Earnings Per Share As Reported | ||||||||||||||||||||||
Net income | $ | 0.85 | $ | 0.84 | $ | 3.08 | $ | 2.61 | ||||||||||||||
Average number of shares outstanding | 22,382 | 23,959 | 23,058 | 24,520 | ||||||||||||||||||
Diluted Earnings Per Share As Reported | ||||||||||||||||||||||
Net income | $ | 0.84 | $ | 0.83 | $ | 3.04 | $ | 2.55 | ||||||||||||||
Average number of shares outstanding | 22,644 | 24,460 | 23,374 | 25,077 | ||||||||||||||||||
Adjusted Earnings Per Share | ||||||||||||||||||||||
Net income | $ | 1.00 | $ | 0.93 | $ | 3.42 | $ | 3.23 | ||||||||||||||
Average number of shares outstanding | 22,382 | 23,959 | 23,058 | 24,520 | ||||||||||||||||||
Adjusted Diluted Earnings Per Share | ||||||||||||||||||||||
Net income | $ | 0.99 | $ | 0.91 | $ | 3.38 | $ | 3.16 | ||||||||||||||
Average number of shares outstanding | 22,644 | 24,460 | 23,374 | 25,077 | ||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | ||||||||||||||||||||||
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2008 AND 2007 |
||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||
Three Months Ended December 31, | Years Ended December 31, | |||||||||||||||||||||
OPERATING STATISTICS | 2008 | 2007 | 2008 | 2007 | ||||||||||||||||||
Net revenue ($000) (d) | ||||||||||||||||||||||
Homecare | $ | 149,816 | $ | 143,125 | $ | 585,891 | $ | 546,872 | ||||||||||||||
Inpatient | 23,398 | 23,927 | 97,895 | 92,995 | ||||||||||||||||||
Continuous care | 32,877 | 30,150 | 124,894 | 115,801 | ||||||||||||||||||
Total before Medicare cap allowance | $ | 206,091 | $ | 197,202 | $ | 808,680 | $ | 755,668 | ||||||||||||||
Medicare cap allowance | (235 | ) | - | (235 | ) | (242 | ) | |||||||||||||||
Total | $ | 205,856 | $ | 197,202 | $ | 808,445 | $ | 755,426 | ||||||||||||||
Net revenue as a percent of total | ||||||||||||||||||||||
before Medicare cap allowance | ||||||||||||||||||||||
Homecare | 72.6 | % | 72.6 | % | 72.5 | % | 72.4 | % | ||||||||||||||
Inpatient | 11.4 | 12.1 | 12.1 | 12.3 | ||||||||||||||||||
Continuous care | 16.0 | 15.3 | 15.4 | 15.3 | ||||||||||||||||||
Total before Medicare cap allowance | 100.0 | 100.0 | 100.0 | 100.0 | ||||||||||||||||||
Medicare cap allowance | (0.1 | ) | - | - | - | |||||||||||||||||
Total | 99.9 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||
Average daily census ("ADC") (days) | ||||||||||||||||||||||
Homecare | 7,458 | 7,121 | 7,374 | 6,966 | ||||||||||||||||||
Nursing home | 3,452 | 3,610 | 3,535 | 3,581 | ||||||||||||||||||
Routine homecare | 10,910 | 10,731 | 10,909 | 10,547 | ||||||||||||||||||
Inpatient | 386 | 417 | 417 | 417 | ||||||||||||||||||
Continuous care | 533 | 512 | 524 | 513 | ||||||||||||||||||
Total | 11,829 | 11,660 | 11,850 | 11,477 | ||||||||||||||||||
Total Admissions | 13,314 | 13,594 | 55,799 | 54,798 | ||||||||||||||||||
Total Discharges | 13,693 | 13,700 | 55,691 | 54,530 | ||||||||||||||||||
Average length of stay (days) | 83.1 | 75.7 | 75.4 | 76.5 | ||||||||||||||||||
Median length of stay (days) | 14.0 | 14.0 | 14.0 | 13.0 | ||||||||||||||||||
ADC by major diagnosis | ||||||||||||||||||||||
Neurological | 33.1 | % | 32.8 | % | 32.7 | % | 33.1 | % | ||||||||||||||
Cancer | 19.3 | 20.4 | 19.8 | 20.1 | ||||||||||||||||||
Cardio | 12.5 | 13.5 | 12.8 | 14.1 | ||||||||||||||||||
Respiratory | 6.5 | 6.8 | 6.6 | 6.8 | ||||||||||||||||||
Other | 28.6 | 26.5 | 28.1 | 25.9 | ||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||
Admissions by major diagnosis | ||||||||||||||||||||||
Neurological | 18.6 | % | 18.5 | % | 18.4 | % | 18.5 | % | ||||||||||||||
Cancer | 35.9 | 36.6 | 35.7 | 36.1 | ||||||||||||||||||
Cardio | 11.1 | 11.9 | 11.6 | 12.6 | ||||||||||||||||||
Respiratory | 7.6 | 7.3 | 7.8 | 7.5 | ||||||||||||||||||
Other | 26.8 | 25.7 | 26.5 | 25.3 | ||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||
Direct patient care margins (e) | ||||||||||||||||||||||
Routine homecare | 53.3 | % | 51.6 | % | 51.7 | % | 51.1 | % | ||||||||||||||
Inpatient | 14.9 | 18.8 | 17.2 | 18.4 | ||||||||||||||||||
Continuous care | 20.1 | 17.6 | 18.1 | 18.0 | ||||||||||||||||||
Homecare margin drivers (dollars per patient day) | ||||||||||||||||||||||
Labor costs | $ | 48.99 | $ | 49.59 | $ | 49.87 | $ | 49.14 | ||||||||||||||
Drug costs | 7.87 | 7.73 | 7.74 | 7.90 | ||||||||||||||||||
Home medical equipment | 6.32 | 5.91 | 6.24 | 5.78 | ||||||||||||||||||
Medical supplies | 2.22 | 2.49 | 2.32 | 2.25 | ||||||||||||||||||
Inpatient margin drivers (dollars per patient day) | ||||||||||||||||||||||
Labor costs | $ | 266.86 | $ | 272.46 | $ | 264.45 | $ | 265.47 | ||||||||||||||
Continuous care margin drivers (dollars per patient day) | ||||||||||||||||||||||
Labor costs | $ | 514.93 | $ | 506.72 | $ | 512.61 | $ | 486.90 | ||||||||||||||
Bad debt expense as a percent of revenues | 1.1 | % | 1.0 | % | 1.0 | % | 0.9 | % | ||||||||||||||
Accounts receivable -- | ||||||||||||||||||||||
days of revenue outstanding | 49.1 | 43.4 | N.A. | N.A. | ||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS | |||||||||||||||||||||||||
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2008 AND 2007 | |||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||
(a) |
Included in the results of operations for the three months and years ended December 31, 2008, are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
||||||||||||||||||||||||
Three Months Ended December 31, 2008 | |||||||||||||||||||||||||
VITAS | Corporate | Consolidated | |||||||||||||||||||||||
Selling, general and administrative expenses | |||||||||||||||||||||||||
Stock option expense | $ | - | $ | (2,219 | ) | $ | (2,219 | ) | |||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
(2 | ) | - | (2 | ) | ||||||||||||||||||||
Other operating expenses/(income) | |||||||||||||||||||||||||
Impairment loss on transportation equipment | - | (2,699 | ) | (2,699 | ) | ||||||||||||||||||||
Gain on extinguishment of debt | - | 4,208 | 4,208 | ||||||||||||||||||||||
Pretax impact on earnings | (2 | ) | (710 | ) | (712 | ) | |||||||||||||||||||
Income tax benefit on the above | 1 | 269 | 270 | ||||||||||||||||||||||
Income tax impact of non-deductible market losses on investments of deferred compensation trusts |
- | (1,825 | ) | (1,825 | ) | ||||||||||||||||||||
After-tax impact on earnings | $ | (1 | ) | $ | (2,266 | ) | $ | (2,267 | ) | ||||||||||||||||
Year Ended December 31, 2008 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Cost of services provided and goods sold | |||||||||||||||||||||||||
Unreserved prior-year's insurance claim | $ | - | $ | (597 | ) | $ | - | $ | (597 | ) | |||||||||||||||
Selling, general and administrative expenses | |||||||||||||||||||||||||
Stock option expense | - | - | (7,303 | ) | (7,303 | ) | |||||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
(46 | ) | - | - | (46 | ) | |||||||||||||||||||
Other operating expenses/(income) | |||||||||||||||||||||||||
Impairment loss on transportation equipment | - | - | (2,699 | ) | (2,699 | ) | |||||||||||||||||||
Gain on extinguishment of debt | - | - | 4,208 | 4,208 | |||||||||||||||||||||
Pretax impact on earnings | (46 | ) | (597 | ) | (5,794 | ) | (6,437 | ) | |||||||||||||||||
Income tax benefit on the above | 18 | 239 | 2,125 | 2,382 | |||||||||||||||||||||
Income tax impact of non-deductible market losses on investments of deferred compensation trusts |
- | - | (3,062 | ) | (3,062 | ) | |||||||||||||||||||
Income tax credit related to prior years | 322 | - | - | 322 | |||||||||||||||||||||
After-tax impact on earnings | $ | 294 | $ | (358 | ) | $ | (6,731 | ) | $ | (6,795 | ) | ||||||||||||||
(b) |
Included in the results of operations for the three months and years ended December 31, 2007, are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
||||||||||||||||||||||||
Three Months Ended December 31, 2007 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses | |||||||||||||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
$ | (39 | ) | $ | - | $ | - | $ | (39 | ) | |||||||||||||||
Stock option expense | - | - | (1,591 | ) | (1,591 | ) | |||||||||||||||||||
Other operating expenses/(income) | |||||||||||||||||||||||||
Costs related to litigation settlement | - | (1,927 | ) | - | (1,927 | ) | |||||||||||||||||||
Pretax impact on earnings | (39 | ) | (1,927 | ) | (1,591 | ) | (3,557 | ) | |||||||||||||||||
Income tax benefit on the above | 15 | 759 | 581 | 1,355 | |||||||||||||||||||||
Income tax impact of non-deductible market losses on investments of deferred compensation trusts |
- | - | 77 | 77 | |||||||||||||||||||||
After-tax impact on earnings | $ | (24 | ) | $ | (1,168 | ) | $ | (933 | ) | $ | (2,125 | ) | |||||||||||||
Year Ended December 31, 2007 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses | |||||||||||||||||||||||||
Long-term incentive compensation | $ | - | $ | - | $ | (7,067 | ) | $ | (7,067 | ) | |||||||||||||||
Expenses incurred in connection with O.I.G. investigation |
(227 | ) | - | - | (227 | ) | |||||||||||||||||||
Stock option expense | - | - | (4,665 | ) | (4,665 | ) | |||||||||||||||||||
Other | - | - | 467 | 467 | |||||||||||||||||||||
Other operating expenses/(income) | |||||||||||||||||||||||||
Costs related to litigation settlement | - | (1,927 | ) | - | (1,927 | ) | |||||||||||||||||||
Gain on sale of property | - | - | 1,138 | 1,138 | |||||||||||||||||||||
Loss on extinguishment of debt | - | - | (13,798 | ) | (13,798 | ) | |||||||||||||||||||
Pretax impact on earnings | (227 | ) | (1,927 | ) | (23,925 | ) | (26,079 | ) | |||||||||||||||||
Income tax benefit on the above | 86 | 759 | 8,778 | 9,623 | |||||||||||||||||||||
Income tax impact of non-deductible market losses on investments of deferred compensation trusts |
- | - | (46 | ) | (46 | ) | |||||||||||||||||||
After-tax impact on earnings | $ | (141 | ) | $ | (1,168 | ) | $ | (15,193 | ) | $ | (16,502 | ) |
(c) |
Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the fourth quarters of 2008 and 2007, GAAP advertising expense for Roto-Rooter totaled $7,421,000 and $7,330,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the fourth quarters of 2008 and 2007 would total $6,020,000 and $5,798,000, respectively. For the years ended December 31, 2008 and 2007, GAAP advertising expense for Roto-Rooter totaled $24,077,000 and $22,980,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the years ended December 31, 2008 and 2007, would total $23,852,000 and $22,379,000, respectively. |
(d) |
VITAS has 6 large (greater than 450 ADC), 16 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. There is one continuing program as of December 31, 2008, with Medicare cap cushion of less than 10% for the 2008 measurement period. There are two continuing programs as of December 31, 2008, with Medicare cap cushion of less than 10% for the 2009 measurement period, including one program with a $235,000 liability recorded at year end. |
(e) | Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation. |
(f) | Reclassified to conform to 2008 presentation. |
CONTACT:
Chemed Corporation
David P. Williams, 513-762-6901